JetBlue shares tumble roughly 20% after disappointing outlook

JetBlue shares tumble roughly 20% after disappointing outlook


A JetBlue Airways plane prepares to take off from the Fort Lauderdale-Hollywood International Airport on January 31, 2024 in Fort Lauderdale, Florida.

Joe Raedle | Getty Images

JetBlue Airways shares tumbled Tuesday after the carrier’s financial outlook disappointed investors.

The New York-based airline forecast its unit costs, excluding fuel, will rise as much as 7% this year from last year. In the first quarter, it said it expected this metric to rise up to 10% this quarter year-over-year.

It estimated revenue could come in as much as 0.5% lower to up to 3.5% higher this quarter over last year. Larger competitors Delta and United have been forecasting higher revenue growth, a sign of stronger airline pricing power.

The carrier expects its 2025 revenue to rise between 3% and 6% on flat capacity.

JetBlue is in the middle of a plan to reduce costs by culling unprofitable routes, deferring aircraft and drumming up revenue with higher-priced seats. CNBC reported on Friday that JetBlue has offered senior pilots voluntary early retirement packages.

JetBlue lost two antitrust cases that blocked two of its growth strategies: In 2024, a federal judge blocked JetBlue’s planned acquisition of Spirit Airlines, which filed for Chapter 11 bankruptcy protection in November, and in 2023, it lost a case over its regional partnership with American Airlines.



Source

Nike cuts 1,400 roles in second round of layoffs this year
Business

Nike cuts 1,400 roles in second round of layoffs this year

People walk past a Nike store in New York City, on April 2, 2025. Kylie Cooper | Reuters Nike announced a new round of layoffs on Thursday impacting approximately 1,400 roles across the organization, mostly concentrated in its technology department. In a note from COO Venkatesh Alagirisamy, the company said the layoffs were part of […]

Read More
Trump administration moves to reclassify cannabis in major shift that could expand research
Business

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration’s controlled […]

Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Business

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]

Read More